Plasma derivatives: New products and new approaches

Biologicals

Volumn 40, Issue 3, 2012, Pages 191-195

  Sauna, Zuben E ^a   Pandey, Gouri Shankar ^a   Jain, Nisha ^a   Mahmood, Ifthekar ^a   Kimchi Sarfaty, Chava ^a   Golding, Basil ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Factor IX; Factor VIII; Hemophilia; Immunogenicity; Pharmacogenetics; Protein therapeutics

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8 DERIVATIVE;

ARTICLE; BLEEDING DISORDER; CHEMICAL MODIFICATION; CHRONIC DISEASE; GENE THERAPY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOGENICITY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; APTAMERS, NUCLEOTIDE; BLOOD COAGULATION FACTORS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; LIPOPROTEINS; PLASMA;

EID: 84860631158     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.11.003     Document Type: Article

References (47)

1. Gilbert M.S. Musculoskeletal complications of haemophilia: the joint. Haemophilia 2000, 6(Suppl. 1):34-37.
2. Roosendaal G., Lafeber F.P. Pathogenesis of haemophilic arthropathy. Haemophilia 2006, 12(Suppl. 3):117-121.
3. Key N.S., Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007, 370:439-448.
4. Hoots W.K. History of plasma-product safety. Transfus Med Rev 2001, 15:3-10.
5. Mannucci P.M., Tuddenham E.G.D. Medical progress - the hemophilias - from royal genes to gene therapy. N Engl J Med 2001, 344:1773-1779.
6. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., Riske B., Hacker M.R., Kilcoyne R., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-544.
7. Berntorp E., Boulyjenkov V., Brettler D., Chandy M., Jones P., Lee C., et al. Modern treatment of haemophilia. Bull W H O 1995, 73:691-701.
8. Butler R.B., McClure W., Wulff K. Practice patterns in haemophilia A therapy-a survey of treatment centres in the United States. Haemophilia 2003, 9:549-554.
9. Geraghty S., Dunkley T., Harrington C., Lindvall K., Maahs J., Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006, 12:75-81.
10. Khair K., Lawrence K., Butler R., O'Shea E., Christie B.A. Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective. Acta Haematol 2008, 119:115-123.
11. Hacker M.R., Page J.H., Shapiro A.D., Rich-Edwards J.W., Manco-Johnson M.J. Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy. J Pediatr Hematol Oncol 2007, 29:458-464.
12. Ewenstein B.M., Valentino L.A., Journeycake J.M., Tarantino M.D., Shapiro A.D., Blanchette V.S., et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004, 10:629-648.
13. Vlot A.J., Mauser-Bunschoten E.P., Zarkova A.G., Haan E., Kruitwagen C.L., Sixma J.J., et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000, 83:65-69.
14. Poon M.C., Aledort L.M., Anderle K., Kunschak M., Morfini M. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 1995, 35:319-323.
15. Lillicrap D. Improvements in factor concentrates. Curr Opin Hematol 2010, 17:393-397.
16. Veronese F.M., Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008, 22:315-329.
17. Bailon P., Won C.Y. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009, 6:1-16.
18. Valentino L.A., Ismael Y., Grygotis M. Novel drugs to treat hemophilia. Expert Opin Emerg Drugs 2010, 15:597-613.
19. Rostin J., Smeds A.L., Akerblom E. B-domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. Bioconj Chem 2000, 11:387-396.
20. Mei B., Pan C., Jiang H., Tjandra H., Strauss J., Chen Y., et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010, 116:270-279.
21. Sterling K. The turnover rate of serum albumin in man as measured by I131-tagged albumin. J Clin Invest 1951, 30:1228-1237.
22. Metzner H.J., Weimer T., Kronthaler U., Lang W., Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009, 102:634-644.
23. Weimer T., Wormsbacher W., Kronthaler U., Lang W., Liebing U., Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008, 99:659-667.
24. Haymann J.P., Levraud J.P., Bouet S., Kappes V., Hagege J., Nguyen G., et al. Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 2000, 11:632-639.
25. Peters R.T., Low S.C., Kamphaus G.D., Dumont J.A., Amari J.V., Lu Q., et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010, 115:2057-2064.
26. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002, 8:280-287.
27. Lacroix-Desmazes S., Navarrete A.M., Andre S., Bayry J., Kaveri S.V., Dasgupta S. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008, 112:240-249.
28. Zhang A.H., Skupsky J., Scott D.W. Factor VIII inhibitors: risk factors and methods for prevention and immune modulation. Clin Rev Allergy Immunol 2009, 37:114-124.
29. Kruglyak L., Nickerson D.A. Variation is the spice of life. Nat Genet 2001, 27:234-236.
30. Krejsa C., Rogge M., Sadee W. Protein therapeutics: new applications for pharmacogenetics. Nat Rev Drug Discov 2006, 5:507-521.
31. Viel K.R., Machiah D.K., Warren D.M., Khachidze M., Buil A., Fernstrom K., et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 2007, 109:3713-3724.
32. Viel K.R., Ameri A., Abshire T.C., Iyer R.V., Watts R.G., Lutcher C., et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009, 360:1618-1627.
33. Aledort L.M., DiMichele D.M. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998, 4:68.
34. Astermark J., Berntorp E., White G.C., Kroner B.L. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development. Haemophilia 2001, 7:267-272.
35. Bray G.L., Gomperts E.D., Courter S., Gruppo R., Gordon E.M., Manco-Johnson M., et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994, 83:2428-2435.
36. Lusher J.M., Arkin S., Abildgaard C.F., Schwartz R.S. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993, 328:453-459.
37. Crawley J.T., Lane D.A. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2008, 28:233-242.
38. Nordfang O., Valentin S., Beck T.C., Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991, 66:464-467.
39. Erhardtsen E., Ezban M., Madsen M.T., Diness V., Glazer S., Hedner U., et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995, 6:388-394.
40. Waters E.K., Genga R.M., Schwartz M.C., Nelson J.A., Schaub R.G., Olson K.A., et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011, 117:5514-5522.
41. Lee J.F., Stovall G.M., Ellington A.D. Aptamer therapeutics advance. Curr Opin Chem Biol 2006, 10:282-289.
42. Ng E.W., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006, 5:123-132.
43. Bouchard P.R., Hutabarat R.M., Thompson K.M. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 2010, 50:237-257.
44. Walter J., High K.A. Gene therapy for the hemophilias. Adv Vet Med 1997, 40:119-134.
45. Hasbrouck N.C., High K.A. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Gene Ther 2008, 15:870-875.
46. Manno C.S., Pierce G.F., Arruda V.R., Glader B., Ragni M., Rasko J.J. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006, 12:342-347.
47. Gouw S.C., Vanderbom J.G., Vandenberg H.M., Zewald R.A., Ploos Vanamstel J.K., Mauser-Bunschoten E.P. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. Haemophilia 2011, 17:275-281.